Eli Lilly and Company, a leader in the weight-loss drug revolution with Mounjaro and Zepbound, experienced a notable earnings-related stock price surge. After a pullback that tested the stock’s ascending support line from $620 to recent highs, the stock jumped 10% on earnings, reinforcing the importance of this trendline.
From September lows near $620, Eli Lilly followed a clean uptrend, reaching close to $1,150. The ascending trendline repeatedly acted as support, with buyers defending it each time, leading to further price increases. This consistent pattern built technical confidence among chart observers.
Ahead of earnings, the stock pulled back to around $1,107 to test the trendline, with uncertainty about whether support would hold. The market responded with a decisive 10% surge in a single session, propelling the stock to trade 7% higher into new territory between $1,185-$1,200.
The recent movement illustrates the psychology in price actions, as those who held or bought during the pullback were rewarded. Traders now observe that the uptrend is reinforced, with potential resistance around the $1,250-$1,280 area. The reinforcement suggests a blend of technical support and fundamental validation.
Looking back to early 2025, we saw Eli Lilly prove its strength by launching 10% off that critical ascending trendline near $1,107. That move validated the bullish technical setup and served as a powerful signal for what was to come. With the stock now trading above $1,550, trusting that support has clearly paid off.
The fundamental picture has only gotten stronger since then, justifying the rally. For instance, Zepbound sales in the final quarter of 2025 crushed estimates, topping $4.5 billion and helping Lilly capture over 55% of new weight-loss prescriptions. This confirms the trend isn’t just a chart pattern; it’s driven by massive demand.
For the coming weeks, this sustained momentum suggests that buying call options remains a viable strategy for bullish exposure. Traders should look at strikes around $1,600 or higher with expirations in late March or April to capture the next potential leg up. This direct approach benefits most from a continued sharp advance.
Given that the stock’s run-up has kept option premiums relatively expensive, we should also consider selling cash-secured puts. By selling puts at a lower strike price, like $1,480, you can collect premium while defining a more attractive entry point if a pullback occurs. This is a way to get paid for your willingness to buy the stock on a dip.
For those concerned about the cost of options, a bull call spread offers a risk-defined alternative. One could buy a $1,550 call and simultaneously sell a $1,600 call to finance the position and cap the potential profit. This strategy lowers the upfront cost and is effective in a steadily rising market.
We need to keep an eye on implied volatility as the next earnings announcement in April approaches. Volatility and option premiums will likely expand in the weeks leading up to the report. This presents opportunities to either position ahead of the event or sell premium into the expected price swings.
